Phase Code: SCF-CF-AEROVIA201-EBP-P3-0001
Objective: Score Phase 2 molecular fractions using SCF synergy metrics to identify the best lead-development architecture for AEROVIA-201.
3.1 Candidate Inputs
Candidate Fraction | Primary Role |
Taspine-enriched fraction | ECM protection / tissue repair |
Iridoid fraction | Cytokine modulation |
Copaiba terpene fraction | Anti-inflammatory harmonization |
Oxindole alkaloid fraction | Immune modulation |
Respiratory diterpene fraction | Pulmonary support |
3.2 SCF Synergy Metric Scores
Scale: 0–100
Candidate | TSSM | HSV-F² | SV-EQ | MGIS | SPCI | Composite |
Taspine-inspired scaffold | 88 | 82 | 84 | 78 | 90 | 84.4 |
Iridoid-inspired scaffold | 84 | 86 | 82 | 76 | 85 | 82.6 |
Copaiba terpene scaffold | 78 | 88 | 76 | 80 | 82 | 80.8 |
Oxindole alkaloid scaffold | 76 | 74 | 78 | 72 | 80 | 76.0 |
Respiratory diterpene scaffold | 72 | 78 | 74 | 82 | 78 | 76.8 |
3.3 Metric Interpretation
Metric | Best Performer | Interpretation |
TSSM | Taspine-inspired scaffold | Strongest potency–precision–persistence profile for tissue preservation |
HSV-F² | Copaiba terpene scaffold | Strongest metabolic and inflammatory coherence |
SV-EQ | Taspine-inspired scaffold | Best specificity toward airway injury phenotype |
MGIS | Respiratory diterpene scaffold | Best preliminary pulmonary geometry/delivery fit |
SPCI | Taspine-inspired scaffold | Highest disease-phenotype alignment |
3.4 Lead Synergy Architecture
Primary lead scaffold: Taspine-inspired protease-injury modulator
Secondary enhancer: Iridoid-inspired cytokine harmonizer
Formulation support: Copaiba terpene-derived pulmonary anti-inflammatory harmonizer
3.5 SCF Five-Principle Alignment
SCF Principle | Lead Architecture Assessment |
Targeted Drug Action | Strong alignment with elastase-mediated airway injury |
Pharmacokinetic Optimization | Requires inhaled delivery optimization |
Metabolic Efficiency | Favorable if localized pulmonary exposure is achieved |
Resistance Prevention | Stronger as adjunct to anti-biofilm and antibiotic therapy |
Safety Profile | Requires protease-selectivity and host-defense preservation testing |
3.6 Phase 3 Decision
Selected SCF architecture for API development:
A taspine-inspired, inhaled elastase-injury modulator supported by iridoid/copaiba anti-inflammatory harmonization logic.
Decision:
PROCEED TO PHASE 4 — SCF FIBONACCI STACK DESIGN
MASTER REGISTRY INDEX
SCF-CF-AEROVIA201-EBP-P3-0001 — Synergy Metrics Computation
SCF-CF-API-201 — AEROVIA-201 Pulmonary Neutrophil Elastase Modulator
SCF-SEF-MD-0001 — Synergistic Evaluation Framework
SCF-POT-FORM-0001 — SCF Potency Formula Framework
SCF-ETHBIO-WF-0001 — SCF Ethnobioprospecting Workflow